Pulmatrix and Cullgen waive no-solicitation clause, explore alternatives due to CSRC delay

Pulmatrix, Inc.

Parties mutually waived the 'No Solicitation' clause (Section 5.4) of the Nov 2024 Merger Agreement.
Waiver permits each party to explore alternate transactions while continuing to pursue CSRC merger approval.
CSRC approval remains the primary unmet closing condition; S-4 effective May 2025, stockholder vote June 2025.
Pulmatrix had $4.8M cash as of Sept 30, 2025, funding operations into at least Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.